Despite the availability of a highly effective cure, approximately 70,000 Australians continue to live with hepatitis C, raising urgent questions about healthcare access and awareness. The treatment, which has been hailed as a medical breakthrough akin to the discovery of penicillin, offers a simple regimen of one pill per day for up to 12 weeks. It has transformed the outlook for many, significantly reducing the risk of severe liver disease and liver cancer.
The cure became accessible in Australia through the Pharmaceutical Benefits Scheme in 2016. Since then, around 62.9 percent of individuals diagnosed with hepatitis C have received treatment. Despite this progress, a troubling statistic reveals that 84 percent of those currently living with the virus are no longer injecting drug users or have contracted it through other means, such as unsafe medical practices before 1990.
Changing Demographics and New Strategies Required
Historically, hepatitis C has been closely associated with injecting drug use. Significant strides have been made in outreach programs targeting this group, including harm reduction initiatives like needle exchange programs. Nonetheless, the demographic landscape is evolving. Many individuals living with hepatitis C today might not fit the traditional profile, having contracted the virus through blood transfusions, unsafe tattoos, or procedures in countries with less stringent health regulations.
In New South Wales, data indicate that approximately 40 percent of hepatitis C retreatments occur within prisons, highlighting the need for continued focus on these facilities as primary sites for virus transmission. Community-led efforts have been effective, but there is a pressing need for strategies that reach those who remain undiagnosed and untreated. This population often includes individuals aged 40 to 65, predominantly male, many of whom may have a history of drug use or unsafe medical procedures.
Addressing Stigma and Enhancing Accessibility
The stigma associated with hepatitis C can deter individuals from seeking necessary testing and treatment. Many in this “missing group” are hesitant to discuss their health history with general practitioners, which underscores the importance of community outreach services. Organizations dedicated to hepatitis care are critical in creating supportive, stigma-free environments that encourage individuals to seek help.
The long-term effects of untreated hepatitis C can be severe, leading to chronic liver inflammation and, ultimately, liver cancer. Most individuals do not exhibit symptoms for years, which complicates early detection and treatment. With effective treatment available, it is unacceptable for anyone to die from a curable disease due to barriers like stigma or lack of knowledge.
In response to this ongoing public health issue, the Australian government has supported initiatives such as HepLink, a confidential service designed to connect individuals with hepatitis-friendly healthcare providers. This initiative allows those concerned about their risk or who may have previously been unaware of their hepatitis C status to access crucial information and support without requiring a Medicare card.
No individual should face the threat of hepatitis C alone. The call to action is clear: Australia must intensify its efforts to eliminate hepatitis C, ensuring that no one is left behind. Those who suspect they may be at risk or who have previously tested positive are encouraged to reach out to services like HepLink at 1800 437 222 or visit www.heplink.au for free and confidential assistance.
